

Phone: 732-390-7750 Fax: 844-683-2244 *AsteraCancerCare.org*PATIENT REFERRAL FORM RHEUMATOLOGY

Patient Name:			Pt. DOB:	J		
Last	First	Middle				
Patient Address:						
			Pt. Zip:			
Patient Phone:()			Pt. Height:	in.		
DX:			Pt. Weight: _	lbs.		
Patient Allergies:						
Insurance:		<del></del>	ID#:			
Referred by:			NPI#:			
Office Contact (Required):		Offi	ce Ph: ()			
		Offi	ice Fax: ( )			
Office Administrator (Required): Adr			tor Ph: ( )			
Astera Infusion Therapy scheduling						
■Edison ■Jersey City ■Monroe	e <b>□</b> Robbinsville	■Rutherford ■Som	erset			
Required Items/Infusion Process	5:					
□ Valid/signed <u>written</u> prescrip	tion including na	me of medication, ex	cact dosage, and dire	ctions		
(prescription only valid for 6	months, includin	g refills)				
☐ Copy of current insurance card	t					
☐ Recent MD consultation notes	: relevant diseas	se being treated must	be mentioned in rep	ort		
<ul> <li>Allergies and current medicati</li> </ul>	on list					
☐ Current labs required for spec	ific medication, a	s noted on the follow	ing page(s) of this fo	rm		
Has the patient initiated treatme	ent at your office	? □ Y	'es □	No		
☐ If any future lab tests are need	ded, please provi	de patient with a pres	scription, and have pa	atient bring on		
day of treatment. Results will be	• •	•		J		
Please note:						

- 1. A Letter of Medical Necessity is required for all patients receiving their initial infusion at Astera (letter must include diagnosis, previous treatments/response to treatments and be on letterhead with physician signature).
- 2. Benefit investigations, copay assistance and prior authorizations will be handled by the Astera precert staff if required by the payer. Right to auto-substitute biosimilars based on payer's preference. Detailed clinical notes providing supportive documentation are required for authorization requests which may take 3-5 business days depending on the payer and receipt of complete documentation from the referring office. The precert staff will update the referring doctor's office during this process and contact the patient to discuss cost and financial assistance options. For certain medications, patients will be required to register/enroll with the pharmaceutical company prior to rendered services and will receive a call from an Astera Financial Counselor to assist with this process.
- 3. A pretreatment education session will be provided by an Advanced Practice Provider.
- 4. Once the infusion is complete, a follow-up notice will be faxed to the to the referring provider.

Patient Name	e:			DOB:	/	/	_		
	Last	First	Middle						
Please check the box for medication requested, attach required documentation as noted below, and fax all documents to our office at 844.683.2244. Once all documentation is received, we will contact your patient to schedule an appointment. Thank you!									
Medication	<u>R</u> (	equired Current Lal	o Results						
Note: Progress	notes and labs m	nust be completed wi	thin the previous 6 mo	onths for all new	and rene	ewed presci	riptions.		
☐ Actemra	CBC, Lipid Panel	, Liver Function, PPD	(prior to initiation)						
☐ Benlysta(IV)	None								
☐ Cimzia	CBC, Prior to initiation – PPD and Hep B Serology (Hep B surface antigen, Hep B surface antibody and Hep core antibody)								
☐ Evenity	CMP, Dexa Scan within 2 years   Confirm pt. has not had an MI or stroke within previous year								
☐ Krystexxa	G6PD Deficienc	y, Serum Uric Acid Le	evels, Confirm Oral Ura	ate Lowering Ag	ent Disco	ntinued			
□ Orencia(IV)	Prior to initiation – PPD and Hep B Serology (Hep B surface antigen, Hep B surface antibody and Hep B core antibody)								
☐ Remicade/In	flectra (Biosimila	r might be replaced i	f appropriate)						

CBC, Liver Function, Prior to initiation – PPD and Hep B Serology (Hep B surface antigen, Hep B

CBC, prior to initiation - Hep B Serology (Hep B surface antigen, Hep B surface antibody and

Up to date with all immunizations before treatment initiation and confirm no live or live

☐ Rituxan/Riabni/Truxima/Ruxience (CMS approved indications only - Biosimilar might be replaced if appropriate)

☐ Simponi Aria(IV) CBC, Liver Function, Prior to initiation — PPD and Hep B Serology (Hep B surface antigen,

surface antibody and Hep B core antibody)

☐ Confirm No Vaccinations within 4 Weeks of Therapy

Hep B surface antibody and Hep B core antibody)

attenuated vaccines are given concurrently.

Gene Testing (GBA – Velaglucerase Alfa)

Hep B core antibody)

☐ Vpriv

☐ Saphnelo